$CCEL
CRYO CELL INTERNATIONAL INC

2023 Q4 Form 10-Q Financial Statement

#000095017023053143 Filed on October 12, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $7.877M $7.870M
YoY Change 1.45% 2.46%
Cost Of Revenue $2.076M $2.156M
YoY Change -2.96% -8.2%
Gross Profit $5.801M $5.714M
YoY Change 3.13% 7.15%
Gross Profit Margin 73.65% 72.6%
Selling, General & Admin $5.393M $3.805M
YoY Change 15.03% 5.58%
% of Gross Profit 92.97% 66.59%
Research & Development $443.8K $344.1K
YoY Change 480.9% 328.71%
% of Gross Profit 7.65% 6.02%
Depreciation & Amortization $335.9K $338.9K
YoY Change -8.99% -8.17%
% of Gross Profit 5.79% 5.93%
Operating Expenses $5.132M $4.149M
YoY Change -1.68% 12.62%
Operating Profit $669.1K $1.161M
YoY Change 65.05% 21.66%
Interest Expense $183.1K $469.6K
YoY Change -195.88% 28.55%
% of Operating Profit 27.36% 40.45%
Other Income/Expense, Net $10.00 -$93.42K
YoY Change -98.67% -70.19%
Pretax Income -$15.99M $1.068M
YoY Change -2669.12% 66.56%
Income Tax -$4.803M $387.1K
% Of Pretax Income 36.25%
Net Earnings -$11.19M $680.6K
YoY Change -1435.61% 45.79%
Net Earnings / Revenue -142.06% 8.65%
Basic Earnings Per Share $0.08
Diluted Earnings Per Share -$1.35 $0.08
COMMON SHARES
Basic Shares Outstanding 8.287M 8.288M
Diluted Shares Outstanding 8.342M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $980.3K $1.207M
YoY Change -43.06% -59.25%
Cash & Equivalents $406.1K $584.0K
Short-Term Investments $574.2K $623.5K
Other Short-Term Assets $390.0K $450.6K
YoY Change -8.65% -64.43%
Inventory $768.9K $1.063M
Prepaid Expenses $615.4K $719.0K
Receivables $6.576M $6.438M
Other Receivables $0.00 $0.00
Total Short-Term Assets $9.453M $9.936M
YoY Change -1.64% -10.81%
LONG-TERM ASSETS
Property, Plant & Equipment $21.00M $18.84M
YoY Change 54.35% 24.1%
Goodwill $1.941M $1.941M
YoY Change 0.0% 0.0%
Intangibles $989.1K $1.391M
YoY Change -32.41% -6.48%
Long-Term Investments $308.0K $308.0K
YoY Change 0.0% 0.0%
Other Assets $30.77M $41.02M
YoY Change -26.16% 1.43%
Total Long-Term Assets $51.77M $59.86M
YoY Change -6.35% 7.61%
TOTAL ASSETS
Total Short-Term Assets $9.453M $9.936M
Total Long-Term Assets $51.77M $59.86M
Total Assets $61.22M $69.80M
YoY Change -5.65% 4.54%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.175M $2.785M
YoY Change 97.76% 55.38%
Accrued Expenses $5.171M $1.774M
YoY Change 44.2% -18.79%
Deferred Revenue $9.705M $9.697M
YoY Change 1.23% 1.57%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $165.6K $162.7K
YoY Change 10.04% 5.45%
Total Short-Term Liabilities $20.86M $18.56M
YoY Change 7.1% -21.42%
LONG-TERM LIABILITIES
Long-Term Debt $8.430M $8.468M
YoY Change -1.75% -1.64%
Other Long-Term Liabilities $51.39M $51.25M
YoY Change 9.5% 12.57%
Total Long-Term Liabilities $51.39M $51.25M
YoY Change 9.5% 12.57%
TOTAL LIABILITIES
Total Short-Term Liabilities $20.86M $18.56M
Total Long-Term Liabilities $51.39M $51.25M
Total Liabilities $72.25M $69.81M
YoY Change 8.79% 0.96%
SHAREHOLDERS EQUITY
Retained Earnings -$31.16M -$19.97M
YoY Change 44.01% -11.15%
Common Stock $43.56M $43.38M
YoY Change 1.9% 1.85%
Preferred Stock
YoY Change
Treasury Stock (at cost) $23.43M $23.43M
YoY Change 3.53% 4.12%
Treasury Stock Shares
Shareholders Equity -$11.03M -$16.16K
YoY Change
Total Liabilities & Shareholders Equity $61.22M $69.80M
YoY Change -5.65% 4.54%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$11.19M $680.6K
YoY Change -1435.61% 45.79%
Depreciation, Depletion And Amortization $335.9K $338.9K
YoY Change -8.99% -8.17%
Cash From Operating Activities $3.344M $1.942M
YoY Change 37.64% -27.76%
INVESTING ACTIVITIES
Capital Expenditures $1.715M $3.291M
YoY Change -6956.9% -129.28%
Acquisitions
YoY Change
Other Investing Activities -$266.7K -$95.25K
YoY Change -114.11% -844.14%
Cash From Investing Activities -$1.982M -$3.386M
YoY Change -203.45% -69.84%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.541M 903.9K
YoY Change -72.32% -89.56%
NET CHANGE
Cash From Operating Activities 3.344M 1.942M
Cash From Investing Activities -1.982M -3.386M
Cash From Financing Activities -1.541M 903.9K
Net Change In Cash -177.9K -540.0K
YoY Change -85.43% -549.07%
FREE CASH FLOW
Cash From Operating Activities $3.344M $1.942M
Capital Expenditures $1.715M $3.291M
Free Cash Flow $1.629M -$1.349M
YoY Change -33.62% -109.68%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Central Index Key
EntityCentralIndexKey
0000862692
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--11-30
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-08-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40767
dei Entity Registrant Name
EntityRegistrantName
CRYO-CELL INTERNATIONAL, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
22-3023093
dei Entity Address Address Line1
EntityAddressAddressLine1
700 Brooker Creek Blvd
dei Entity Address City Or Town
EntityAddressCityOrTown
Oldsmar
dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
34677
dei City Area Code
CityAreaCode
813
dei Local Phone Number
LocalPhoneNumber
749-2100
dei Security12b Title
Security12bTitle
Common Stock, $0.01 par value
dei Trading Symbol
TradingSymbol
CCEL
dei Security Exchange Name
SecurityExchangeName
NYSEAMER
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
8286785
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
583996
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1703958
CY2023Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
623489
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
17620
CY2023Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
3757884
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
3528119
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6437644
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6043941
CY2023Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
719007
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
566557
CY2023Q3 us-gaap Inventory Net
InventoryNet
1062859
CY2022Q4 us-gaap Inventory Net
InventoryNet
851230
CY2023Q3 us-gaap Derivative Fair Value Of Derivative Asset
DerivativeFairValueOfDerivativeAsset
58757
CY2022Q4 us-gaap Derivative Fair Value Of Derivative Asset
DerivativeFairValueOfDerivativeAsset
0
CY2023Q3 us-gaap Other Assets Current
OtherAssetsCurrent
450617
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
426879
CY2023Q3 us-gaap Assets Current
AssetsCurrent
9936369
CY2022Q4 us-gaap Assets Current
AssetsCurrent
9610185
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
18836456
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13603115
CY2023Q3 ccel Duke License Agreement
DukeLicenseAgreement
12970447
CY2022Q4 ccel Duke License Agreement
DukeLicenseAgreement
13691028
CY2023Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1391026
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1463312
CY2023Q3 us-gaap Inventory Noncurrent
InventoryNoncurrent
8836287
CY2022Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
9275344
CY2023Q3 us-gaap Goodwill
Goodwill
1941411
CY2022Q4 us-gaap Goodwill
Goodwill
1941411
CY2023Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
13742399
CY2022Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
13742399
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1107171
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
606034
CY2023Q3 ccel Deposits And Other Assets
DepositsAndOtherAssets
726800
CY2022Q4 ccel Deposits And Other Assets
DepositsAndOtherAssets
647226
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
41023541
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
41674754
CY2023Q3 us-gaap Assets
Assets
69796366
CY2022Q4 us-gaap Assets
Assets
64888054
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2785459
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1605301
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1774456
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3585810
CY2023Q3 us-gaap Notes Payable Current
NotesPayableCurrent
162659
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
150527
CY2023Q3 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
2722728
CY2022Q4 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
2272728
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
221062
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
297691
CY2023Q3 ccel Duke License Agreement Liability Current
DukeLicenseAgreementLiabilityCurrent
1200000
CY2022Q4 ccel Duke License Agreement Liability Current
DukeLicenseAgreementLiabilityCurrent
1983036
CY2023Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
9696530
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
9586327
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
18562894
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
19481420
CY2023Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
39966150
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
36000059
CY2023Q3 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
1030050
CY2022Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
1162704
CY2023Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
8468312
CY2022Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
8579875
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
910123
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
313298
CY2023Q3 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
875000
CY2022Q4 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
875000
CY2023Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
51249635
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
46930936
CY2023Q3 us-gaap Liabilities
Liabilities
69812529
CY2022Q4 us-gaap Liabilities
Liabilities
66412356
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14849246
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8286785
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14848001
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8500511
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
148492
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
148480
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
43236194
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
42597380
CY2023Q3 us-gaap Treasury Stock Value
TreasuryStockValue
23431685
CY2022Q4 us-gaap Treasury Stock Value
TreasuryStockValue
22632649
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-19969164
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-21637513
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-16163
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-1524302
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
69796366
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
64888054
CY2023Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
7869875
CY2022Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
7680959
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
23466980
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
22572707
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2156187
CY2022Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2348755
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
6366737
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
6653497
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3804564
CY2022Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3603411
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
11722435
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
10891951
CY2023Q3 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
122671
CY2022Q3 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
412307
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-65154
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
259769
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
344132
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
80272
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
727648
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
308388
CY2023Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
281277
CY2022Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
281903
us-gaap Depreciation And Amortization
DepreciationAndAmortization
843201
us-gaap Depreciation And Amortization
DepreciationAndAmortization
839995
CY2023Q3 us-gaap Costs And Expenses
CostsAndExpenses
6708831
CY2022Q3 us-gaap Costs And Expenses
CostsAndExpenses
6726648
us-gaap Costs And Expenses
CostsAndExpenses
19594867
us-gaap Costs And Expenses
CostsAndExpenses
18953600
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
1161044
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
954311
us-gaap Operating Income Loss
OperatingIncomeLoss
3872113
us-gaap Operating Income Loss
OperatingIncomeLoss
3619107
CY2023Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
93386
CY2022Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-11627
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
100082
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-38457
CY2023Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
282731
CY2022Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
62835
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
58757
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
62835
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
102
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
796
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3436
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
923
CY2023Q3 us-gaap Interest Expense
InterestExpense
469642
CY2022Q3 us-gaap Interest Expense
InterestExpense
365349
us-gaap Interest Expense
InterestExpense
1405825
us-gaap Interest Expense
InterestExpense
947968
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-93423
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-313345
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1243550
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-922667
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
1067621
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
640966
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
2628563
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
2696440
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
387060
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
174146
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
960214
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
762854
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
680561
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
466820
us-gaap Net Income Loss
NetIncomeLoss
1668349
us-gaap Net Income Loss
NetIncomeLoss
1933586
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.08
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.06
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.2
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.23
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8286555
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8390335
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8358792
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8449277
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.08
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.06
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.2
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.23
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8342067
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8404485
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8374939
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8475661
us-gaap Profit Loss
ProfitLoss
1668349
us-gaap Profit Loss
ProfitLoss
1933586
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1063771
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1129804
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-65154
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
259769
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
100082
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-38457
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
58757
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
62835
us-gaap Share Based Compensation
ShareBasedCompensation
641690
us-gaap Share Based Compensation
ShareBasedCompensation
310441
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
717052
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
634405
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
16259
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
10368
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
236730
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
231825
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1110755
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
727905
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
152450
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
86433
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-227428
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-303162
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
23738
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
555591
ccel Increase Decrease In Deposits And Other Assets
IncreaseDecreaseInDepositsAndOtherAssets
79574
ccel Increase Decrease In Deposits And Other Assets
IncreaseDecreaseInDepositsAndOtherAssets
59272
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
550266
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
302876
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1814218
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-872298
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-217671
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-232709
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
4076294
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
3585261
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
5575440
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
6142911
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5124056
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
12193470
ccel Payment Of Duke License Agreement
PaymentOfDukeLicenseAgreement
533333
ccel Payment Of Duke License Agreement
PaymentOfDukeLicenseAgreement
5000000
ccel Proceeds From Liquidation Of Marketable Securities
ProceedsFromLiquidationOfMarketableSecurities
179306
ccel Proceeds From Liquidation Of Marketable Securities
ProceedsFromLiquidationOfMarketableSecurities
0
ccel Payments To Acquire Marketable Securities And Other Investments
PaymentsToAcquireMarketableSecuritiesAndOtherInvestments
1082924
ccel Payments To Acquire Marketable Securities And Other Investments
PaymentsToAcquireMarketableSecuritiesAndOtherInvestments
1142212
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
397831
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
1140472
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6163176
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-17195210
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
799036
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
1692433
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
115690
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1908433
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
500000
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
0
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
551274
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
950000
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
0
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
8960000
ccel Issuance Costs Associated With The Proceeds From The Note Payable
IssuanceCostsAssociatedWithTheProceedsFromTheNotePayable
0
ccel Issuance Costs Associated With The Proceeds From The Note Payable
IssuanceCostsAssociatedWithTheProceedsFromTheNotePayable
-196501
ccel Payment Of Earnout
PaymentOfEarnout
67500
ccel Payment Of Earnout
PaymentOfEarnout
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-532226
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5713907
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-1119962
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-5338392
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1703958
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
8263088
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
583996
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2924696
ccel Lease Liability Arising From Right Of Use Asset
LeaseLiabilityArisingFromRightOfUseAsset
737867
ccel Lease Liability Arising From Right Of Use Asset
LeaseLiabilityArisingFromRightOfUseAsset
0
ccel Construction Costs Payable
ConstructionCostsPayable
363225
ccel Construction Costs Payable
ConstructionCostsPayable
0
ccel Duke License Agreement Payable
DukeLicenseAgreementPayable
266667
ccel Duke License Agreement Payable
DukeLicenseAgreementPayable
0
ccel Dividends Declared But Not Yet Paid
DividendsDeclaredButNotYetPaid
0
ccel Dividends Declared But Not Yet Paid
DividendsDeclaredButNotYetPaid
7672728
us-gaap Interest Paid Net
InterestPaidNet
1363934
us-gaap Interest Paid Net
InterestPaidNet
776517
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
1504647
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
1377133
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-858375
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
-2864
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
172099
CY2023Q3 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
7584
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
680561
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-16163
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-1524302
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
-2864
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
641690
us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
799036
us-gaap Net Income Loss
NetIncomeLoss
1668349
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-16163
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
4406983
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
519274
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
161083
CY2022Q3 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
266978
CY2022Q3 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.9
CY2022Q3 us-gaap Dividends Common Stock
DividendsCommonStock
7672728
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
466820
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-2385546
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
4184314
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
551274
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
310441
us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
1692433
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.9
us-gaap Dividends Common Stock
DividendsCommonStock
7672728
us-gaap Net Income Loss
NetIncomeLoss
1933586
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-2385546
CY2023Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
49662680
CY2023Q3 ccel Revenue Remaining Performance Obligation Next Twelve Months
RevenueRemainingPerformanceObligationNextTwelveMonths
9696530
CY2023Q3 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P12M
CY2005Q4 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
50000
CY2005Q4 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
50000
CY2012Q1 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
75000
CY2017Q2 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
100000
CY2023Q3 us-gaap Sales Commissions And Fees
SalesCommissionsAndFees
10061
us-gaap Sales Commissions And Fees
SalesCommissionsAndFees
31451
CY2022Q3 us-gaap Sales Commissions And Fees
SalesCommissionsAndFees
11151
us-gaap Sales Commissions And Fees
SalesCommissionsAndFees
38471
CY2023Q3 ccel Increase Decrease In Capitalized Contract Cost
IncreaseDecreaseInCapitalizedContractCost
30185
ccel Increase Decrease In Capitalized Contract Cost
IncreaseDecreaseInCapitalizedContractCost
85133
CY2022Q3 ccel Increase Decrease In Capitalized Contract Cost
IncreaseDecreaseInCapitalizedContractCost
29269
ccel Increase Decrease In Capitalized Contract Cost
IncreaseDecreaseInCapitalizedContractCost
81028
CY2023Q3 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
675652
CY2022Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
615628
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6437644
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6043941
CY2023Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
9696530
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
9586327
CY2023Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
39966150
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
36000059
CY2023Q3 ccel Impairment Of Contract Assets
ImpairmentOfContractAssets
0
ccel Impairment Of Contract Assets
ImpairmentOfContractAssets
0
CY2022Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
615628
ccel Contract With Customer Asset Net Current Additions
ContractWithCustomerAssetNetCurrentAdditions
85133
ccel Contract With Customer Asset Net Current Deductions
ContractWithCustomerAssetNetCurrentDeductions
25109
CY2023Q3 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
675652
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6043941
ccel Accounts Receivable Net Current Additions
AccountsReceivableNetCurrentAdditions
31533062
ccel Accounts Receivable Net Current Deductions
AccountsReceivableNetCurrentDeductions
31139359
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6437644
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
45586386
ccel Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
20676740
ccel Contract With Customer Liability Deductions
ContractWithCustomerLiabilityDeductions
16600446
CY2023Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
49662680
CY2021Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
535522
ccel Contract With Customer Asset Net Current Additions
ContractWithCustomerAssetNetCurrentAdditions
81028
ccel Contract With Customer Asset Net Current Deductions
ContractWithCustomerAssetNetCurrentDeductions
21756
CY2022Q3 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
594794
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5253173
ccel Accounts Receivable Net Current Additions
AccountsReceivableNetCurrentAdditions
28203957
ccel Accounts Receivable Net Current Deductions
AccountsReceivableNetCurrentDeductions
28110457
CY2022Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5346673
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
40632910
ccel Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
18481419
ccel Contract With Customer Liability Deductions
ContractWithCustomerLiabilityDeductions
14896158
CY2022Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
44218171
CY2023Q3 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
CY2023Q3 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2022Q3 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
641690
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
310441
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
172099
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
161083
us-gaap Interest Expense
InterestExpense
1405825
CY2023Q3 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
93386
us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
100082
CY2022Q3 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
-11627
us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
-38457
CY2023Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
282731
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
58757
CY2022Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
62835
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
62835
us-gaap Guarantees Indemnifications And Warranties Policies
GuaranteesIndemnificationsAndWarrantiesPolicies
<p style="text-indent:0;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">Product Warranty and Cryo-Cell Cares</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:'Times New Roman',serif;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> Program</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">In December 2005, the Company began providing its customers that enrolled after December 2005 a payment warranty under which the Company agrees to pay $</span><span style="font-size:10pt;font-family:'Times New Roman',serif;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">50,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> to its client if the umbilical cord blood product retrieved is used for a stem cell transplant for the donor or an immediate family member and fails to engraft, subject to various restrictions. Effective February 1, 2012, the Company increased the $</span><span style="font-size:10pt;font-family:'Times New Roman',serif;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">50,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> payment warranty to a $</span><span style="font-size:10pt;font-family:'Times New Roman',serif;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">75,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> payment warranty to all of its new clients. Effective June 1, 2017, the Company increased the payment warranty to $</span><span style="font-size:10pt;font-family:'Times New Roman',serif;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">100,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> to all new clients who choose the premium processing method, PrepaCyte CB. The product warranty is available to clients who enroll under this structure for as long as the specimen is stored with the Company. The Company has not experienced any claims under the warranty program nor has it incurred costs related to these warranties.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">As discussed above, the Company has determined that the payment warranty represents variable consideration payable to the customer. In accordance with ASC 606, the Company has concluded the payment warranty be fully constrained under the most likely amount method; therefore, the transaction price does not reflect any expectation of service level credits at August 31, 2023 and November 30, 2022</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">. At the end of each reporting period, the Company shall update the estimated transaction price related to the payment guarantee including updating its assessment of whether an estimate of variable consideration is constrained to represent faithfully the circumstances present at the end of the reporting period and the changes in circumstances during the reporting period.</span></p>
CY2005Q4 ccel Payment Warranty
PaymentWarranty
50000
CY2005Q4 ccel Payment Warranty
PaymentWarranty
50000
CY2012Q1 ccel Increased Payment Warranty
IncreasedPaymentWarranty
75000
CY2017Q2 ccel Increased Payment Warranty
IncreasedPaymentWarranty
100000
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3
CY2023Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
7869875
CY2022Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
7680959
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2156187
CY2022Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2348755
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
1161044
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
954311
CY2023Q3 us-gaap Interest Expense
InterestExpense
469642
CY2022Q3 us-gaap Interest Expense
InterestExpense
365349
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
23466980
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
22572707
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
6366737
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
6653497
us-gaap Operating Income Loss
OperatingIncomeLoss
3872113
us-gaap Operating Income Loss
OperatingIncomeLoss
3619107
us-gaap Interest Expense
InterestExpense
947968
CY2023Q3 us-gaap Assets
Assets
69796366
CY2022Q4 us-gaap Assets
Assets
64888054
CY2023Q3 ccel Inventory Collection Kits
InventoryCollectionKits
42437
CY2022Q4 ccel Inventory Collection Kits
InventoryCollectionKits
41463
CY2023Q3 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
7718
CY2022Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
7718
CY2023Q3 ccel Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
9899146
CY2022Q4 ccel Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
10126574
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1391026
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1463312
CY2023Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
24000
CY2022Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
24000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
72000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
72000
CY2023Q3 us-gaap Ratio Of Indebtedness To Net Capital1
RatioOfIndebtednessToNetCapital1
3.5
ccel Minimum Debt Service Coverage Ratio
MinimumDebtServiceCoverageRatio
1.25
CY2023Q3 us-gaap Long Term Debt
LongTermDebt
8630971
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
8730402
CY2023Q3 us-gaap Notes Payable Current
NotesPayableCurrent
162659
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
150527
CY2023Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
8468312
CY2022Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
8579875
CY2023Q3 us-gaap Long Term Debt
LongTermDebt
8630971
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
8730402
CY2023Q3 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
206034
us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
623577
CY2022Q3 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
90547
us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
118438
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
680561
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
466820
us-gaap Net Income Loss
NetIncomeLoss
1668349
us-gaap Net Income Loss
NetIncomeLoss
1933586
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8286555
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8390335
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8358792
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8449277
CY2023Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
55512
CY2022Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
14150
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
16147
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
26384
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8342067
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8404485
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8374939
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8475661
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.08
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.06
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.2
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.23
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.08
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.06
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.2
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.23
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
655678
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
730678
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
690464
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
518850
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.19
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.56
CY2023Q3 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
393678
us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P4Y7M2D
CY2023Q3 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
7.42
CY2023Q3 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
285735
CY2023Q3 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
7.52
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
95486
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
4.42
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
113000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.19
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
100543
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
3.33
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
0
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
0
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
107943
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
3.1
CY2022Q3 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.9
CY2022Q3 us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
7672728
CY2011Q4 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
1000000
CY2012Q2 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
3000000
CY2015Q2 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
6000000
CY2016Q4 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
8000000
us-gaap Treasury Stock Acquired Repurchase Authorization
TreasuryStockAcquiredRepurchaseAuthorization
open market purchases, privately negotiated block trades, unsolicited negotiated transactions, and/or pursuant to any trading plan that may be adopted in accordance with Rule 10b5-1 of the Securities and Exchange Commission
CY2023Q3 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
6562461
CY2022Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
6347490
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1107171
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
606034
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
221062
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
297691
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
910123
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
313298
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1131185
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
610989
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
76690
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
306762
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
435970
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
458026
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
38247
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
184510
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1131185
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y3M29D
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y29D
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.083
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.035
CY2023Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
76690
CY2022Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
83378
us-gaap Operating Lease Payments
OperatingLeasePayments
254003
us-gaap Operating Lease Payments
OperatingLeasePayments
255306

Files In Submission

Name View Source Status
ccel-20230831_lab.xml Edgar Link unprocessable
ccel-20230831_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
0000950170-23-053143-index-headers.html Edgar Link pending
0000950170-23-053143-index.html Edgar Link pending
0000950170-23-053143.txt Edgar Link pending
0000950170-23-053143-xbrl.zip Edgar Link pending
ccel-20230831.htm Edgar Link pending
ccel-20230831.xsd Edgar Link pending
ccel-ex31_1.htm Edgar Link pending
ccel-ex31_2.htm Edgar Link pending
ccel-ex31_3.htm Edgar Link pending
ccel-ex32_1.htm Edgar Link pending
ccel-20230831_def.xml Edgar Link unprocessable
ccel-20230831_pre.xml Edgar Link unprocessable
ccel-20230831_htm.xml Edgar Link completed
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending